Effects of Molidustat in the Treatment of Anemia in Chronic Kidney Disease.
CONCLUSIONS: The overall phase 2 efficacy and safety profile of molidustat in patients with CKD and anemia enables the progression of its development into phase 3.
PMID: 30559105 [PubMed - as supplied by publisher]
Source: Clinical Journal of the American Society of Nephrology : CJASN - Category: Urology & Nephrology Authors: Macdougall IC, Akizawa T, Berns JS, Bernhardt T, Krueger T Tags: Clin J Am Soc Nephrol Source Type: research